Triple-Drug combo aims to stop AML relapse after remission
NCT ID NCT07521124
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study tests whether a combination of three drugs (chidamide, venetoclax, and azacitidine) can help prevent acute myeloid leukemia (AML) from coming back in patients who have already achieved remission. About 104 adults aged 18 to 80 will receive up to 12 cycles of treatment. The goal is to see if this maintenance therapy improves relapse-free survival.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- chidamide, venetoclax, and azacitidine
- What this could lead to
- If successful, this maintenance regimen could help keep AML in remission longer and reduce the chance of relapse.
- What could go wrong
- This is an early-phase study with no phase specified, so results are uncertain. The combination may cause side effects and may not improve survival.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA (AML) IN REMISSION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Union Hospital, Tongji Medical College, Huazhong University of Science and Technolog
Wuhan, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.